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ABSTRACT:
Strigolactones are a novel class of plant hormones produced in roots and regulate 
shoot and root development. We have previously shown that synthetic strigolactone 
analogues potently inhibit growth of breast cancer cells and breast cancer stem cells. 
Here we show that strigolactone analogues inhibit the growth and survival of an array 
of cancer-derived cell lines representing solid and non-solid cancer cells including: 
prostate, colon, lung, melanoma, osteosarcoma and leukemic cell lines, while 
normal cells were minimally affected. Treatment of cancer cells with strigolactone 
analogues was hallmarked by activation of the stress-related MAPKs: p38 and JNK and 
induction of stress-related genes; cell cycle arrest and apoptosis evident by increased 
percentages of cells in the sub-G1 fraction and Annexin V staining. In addition, we 
tested the response of patient-matched conditionally reprogrammed primary prostate 
normal and cancer cells. The tumor cells exhibited significantly higher sensitivity 
to the two most potent SL analogues with increased apoptosis confirmed by PARP1 
cleavage compared to their normal counterpart cells. Thus, Strigolactone analogues 
are promising candidates for anticancer therapy by their ability to specifically induce 
cell cycle arrest, cellular stress and apoptosis in tumor cells with minimal effects on 
growth and survival of normal cells.
INTRODUCTION
The strigolactones (SLs) are members of a class of 
plant hormones that control shoot branching architecture 
by inhibiting growth and self renewal of axillary meristem 
cells [1, 2]. We have recently shown that strigolactone 
analogues induce growth arrest and apoptosis in breast 
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cancer cell lines [3], thereby adding the SLs to the list of 
plant-derived effective anti-cancer agents that are being 
assessed for their ability to inhibit the growth and survival 
of human cancer cell lines [4-6] [7, 8] [9, 10]. 
The p38 MAPK is a member of the conserved 
MAPK family of dual serine-theronine kinases that 
respond to variety of internal and external stimuli. The 
p38-MAPK pathway is comprised of four genes; α, β, 
γ, δ with p38α being the most abundant isoform [11]. 
p38α responds to many stress stimuli including reactive 
oxygen species, UV irradiation, hypoxia, and pro- 
inflammatory cytokines. Considerable data imply that 
P38α functions as a tumor suppressor, inducing cell cycle 
arrest, differentiation and apoptosis [11, 12]. Mutations in 
(p38α) were identified by massive parallel sequencing in 
human tumors [11, 13] and xenografts of cells deficient 
in p38α signaling exhibited higher tumor burden than 
their wild type counterparts [14-17]. Furthermore, p38 
was found to be a marker for tumor dormancy and as an 
inhibitor of self-renewal [18]. Conversely, recent reports 
have suggested that p38α is involved in cell survival 
and increased invasion in prostate cancer cells and other 
advanced tumor types [19-21], suggesting an addiction 
to p38 MAPK activity that was correlated with poor 
prognosis [22]. Thus, the role and function of p38 in 
tumorigenesis is complex and may be tissue and context 
dependent. 
The Jun N-terminal Kinase (JNK) pathway also 
plays a major role in cellular stress response. JNK1 and 
JNK2 are the most abundantly expressed isoforms of the 
JNK family. JNK1/2 exert their effects via regulation of 
multiple target genes that contain binding sites for the 
transcription factor, AP1 (JUN-FOS)[11, 23]. As with 
p38, JNK1/2 have been described as either negative or 
positive regulators of cell growth and have been associated 
with both pro-apoptotic and pro-survival activities. 
Recent studies have found that JNK activation enhanced 
chemotherapy-induced apoptosis in multiple cancer cells 
[11], while in prostate cancer, especially in tumors that 
harbor mutations in PTEN, activated JNK1/2 supports 
proliferation and survival [23, 24]. Collectively it appears 
that the type of response depends on intensity and duration 
of the signals as well as cell type. 
Mechanistically, the JNK and p38 MAPK pathways 
share several upstream regulators and there is evidence 
of cooperation and synergy between downstream targets 
such as HSP27, HSP70 and FOXO4 [25, 26]. Perhaps one 
reason for overexpression and constitutive activation of 
the stressed-related pathways in prostate and other types 
of advanced tumors is the constant insults present in the 
cancer cell per se including enhanced DNA damage and 
accumulation of reactive oxygen species [27]. 
Our previous work had found that the growth arrest 
and apoptosis induced by SL analogues in breast cancer 
cell lines occur in part through the activation of the stress 
activated MAPKs, p38 and JNK1/2 and reductions in 
ERK1/2 and AKT activity. Here we further define the 
mechanisms of action, as well as the overall applicability 
of SLs as cancer therapeutics. We show that strigolactone 
analogues changes the genomic landscape of cells and 
despite cells addiction to stress signaling, SL are capable of 
eliciting a significant stress response including induction 
of multiple heat shock proteins, phosphorylation of 
p38MAPK and JNK1/2 and induction of their targets such 
as HSP27, HSP70 and FOXO4 [25, 26]. In addition, we 
employed the new cell culture technology of conditionally 
reprogrammed primary cells (CRCs) that were established 
from patient-matched prostate normal and tumor tissues. 
The reprogrammed cells can grow indefinitely in the 
presence of irradiated feeder cells and ROCK inhibitor and 
can model individual patient responses [28, 29].
Prostate tumor CRCs, are significantly more 
sensitive to SLs than their patient-matched normal CRCs. 
Together, we show that SL analogues produce their 
cytotoxic effect in part through activating p38 MAPK and 
a prolonged stress response in both transformed cell lines 
and in patient-derived CRCs. 
RESULTS
Strigolactone analogues are effective growth 
inhibitors of a diverse range of cancer derived 
cell lines
To determine whether synthetic SL analogues inhibit 
the proliferation of cell lines derived from different types 
of cancers, a diverse cohort of human cancer lines was 
collected comprising prostate, colon, lung, osteosarcoma, 
and leukemia derived lines. Cancer cell lines and BJ 
normal fibroblast cells were treated with each SL analogue 
at a dose range of 1 to 20 ppm (equivalent to 2-60 µM; 
Figure 1, Figure S1A and Table 1). After 3 days, XTT 
cell proliferation assays were carried out and the changes 
in proliferation and cell survival and are presented as a 
percent of vehicle controls. All five SL analogues (EG5, 
EG9c, ST357, ST362 and MEB55) inhibited cancer 
cell growth albeit to varying degrees. In general, ST362 
and MEB55 were the most potent inhibitors with the 
concentrations required to achieve 50% inhibition of cell 
viability (IC50) at day 3 of treatment ranging from 2.8 
ppm to 12.8 ppm. EG5, EG9c and ST357 were less potent 
inhibitors of prostate, colon and lung cancer cell growth 
with IC50 values are mostly above 15 ppm. Interestingly 
the Osteosarcoma-derived line, U2OS exhibited a similar 
sensitivity to all SL analogues tested (IC50 = 2.7 to 4.5 
ppm). None of the analogues tested-reached IC50 values 
in concentrations of up to 20 ppm in non-transformed BJ 
fibroblast cells (Figure 1). Table 1 summarizes the IC50 
values for each cell line. 
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Table 1: The inhibitory concentrations (IC50) of Strigolactone analogues for cancer cells. Mean values are derived 
from 4 replicates of at least  two independent experiments. The conversion between PPM and molarity is given for each 
analogue. 
Tumor 
Cell Lines
IC50 (ppm) at 72 h
EG5
1ppm= 2.3 µM
EG9C
1ppm=3.2 µM
ST357
1 ppm=2.5 µM
ST362
1 ppm=2.0 µM     
MEB55
1 ppm = 3.1 µM
Prostate
  PC3
  DU145
  LNCaP
>15
  13  
>15
>15
>15
11.5
5.0
8.5
11.4
10.3
7.5
2.5
8.8
10.8
2.99
Colon
  HT-29
  HCT116
  SW480
>15
>15
>15
>15
>15
>15
>15
>15
>15
7.3
5.2
2.9
8.2
10.4
9.7
Lung
  A549 4.7 15.5 4.9 5.2 5.1
Osteosarcoma
  U20S 3.9 4.5 4.5 2.8 2.7
Non-tumor  cells
  BJ Fibroblasts ND >20 >20 ND >20
Figure 1: Strigolactone analogues induce cell death in human cancer cell lines. A. Cancer cell lines from the prostate; 
LNCaP, DU145 and PC3, Colon; HT29, HCT116 SW480, Osteosarcoma; U2OS and Lung; A549, as well as the normal BJ fibroblast 
cell line were seeded into 96 well plates in normal growing media. The following day media was replaced with phenol red-free DMEM 
supplemented with 10% charcoal stripped serum and the indicated doses of Strigolactone analogues (four replicates for each treatment 
group or vehicle control). Cell viability was assayed by XTT after 3 days. Graphs are representative of the mean ± standard deviations (SD) 
of two independent experiments. 
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Strigolactone analogues inhibit cyclin B 
expression and induce a G2/M cell cycle arrest 
To assess the effect of SL treatment on the cell cycle, 
HCT116 (colon) and DU145 (prostate) cancer cells were 
treated with the SL analogues ST357, ST362 and MEB55 
(chosen for their lower IC50 doses, see Table 1) for 48 hrs 
and cell cycle distribution was analyzed by flow cytometry 
following propidium iodide (PI) staining (Figure 2A). SL 
treatments induced significant increases in the proportion 
of cells in the G2/M phase and a concomitant decrease 
in the G1 fraction (p<0.0001) in all conditions studied 
with the exception of DU145 cells treated with 10 ppm of 
ST357 (p≤0.28). In addition, increased percentages of cells 
in the sub-G1 fraction were observed, indicating increased 
apoptosis (Figure 2A) (p< 0.0001). SLs treatment had 
similar effect on additional cancer lines (Figure S2). 
Histone H3 phosphorylation on serine 10 (H3pS10) 
was used as a marker to distinguish between G2 and M 
arrest following SL treatment [30]. A reduction in the 
mitotic fraction in HCT116 cells from 2.7% in untreated 
cells to 0.9% and 0.3% in cells treated with 7.5 ppm 
ST362 and MEB55 respectively indicate that cells arrest at 
Figure 2: Effects of SL analogues on cell cycle regulation. A, The cell cycle distribution of HCT116 colon cancer and DU145 
prostate cancer cells treated with the indicated doses of strigolactone analogues for 48 hr was analyzed by flow cytometry. Bar graphs 
represent mean ±SD of at least two experiments. *** P<0.001 as analyzed by Student t-test. B. The percent of treated HCT116 cells in M 
phase (green boxes and numbers) as assessed by FACS analysis of phospho-Ser10 Histone-H3 (vertical) versus DNA content (horizontal) 
is shown. The cells were treated with 5.0 or 7.5 ppm of either ST357 (middle panels or MEB55 (lower panels) and harvested after 48 hr. 
Immunoblot analyses of cell cycle regulatory proteins. DU145 cells were treated with 10 ppm of MEB or vehicle alone for the indicated 
times and the levels of cyclin B, Cdc25C, Cdk1 and Thr14-Cdk1 were determined. D. qRT-PCR for cyclin B1 mRNA expression in DU145 
and HCT116 cells treated with vehicle or 10 ppm of MEB55. The experiment was repeated twice and graphs represent mean ± SD of 
triplicate wells from each experiment is shown vs. controls. * P<0.05, ** P<0.01 as analyzed by Student t-test. E. Cyclin B1 protein levels 
following proteasomal inhibition in DU145 cells treated with MEB55 or ST362. The cells were exposed to SLs for 24 hr prior and then 
treated with 10 mM ALLN for additional 4 (+4) or 8 (+8) hrs. 
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the G2 rather than the M fraction of the cell cycle (Figure 
2B).
Cell cycle progression from G2 to mitosis is 
dependent on the timely accumulation and activation of 
the Cyclin B1/ Cdk1 complex [31]. Dephosphorylation 
of Cdk1 at threonine 14 is a critical step for the complex 
activation. Cyclin B1 levels are significantly decreased 
following 24 hrs of SL treatment in DU145 (Figure 
2C) and HCT116 (Figure 2D) and so is the expression 
level of Cdc25C, the phosphatase responsible for Cdk1 
dephosphorylation and activation (Figure 2C). However, 
no changes in protein levels or Cdk1 phosphorylation 
status at Thr14 were noted. 
Cyclin B1 levels are regulated by several 
mechanisms including transcription and post-translational 
modifications that alter its stability. Quantitative Real-
time PCR (qRT-PCR) revealed a two-fold or more 
decrease in cyclin B1 mRNA in HCT116 and DU145 
respectively, following treatment with 10 ppm of MEB55 
compared to vehicle controls (Figure 2D). We also found 
that SL analogues regulated cyclin B1 protein stability. 
Proteasome inhibition with ALLN for 4 or 8 hrs following 
24 hrs exposure of DU145 cells to MEB55 or ST362 
induced a partial rescue (ST362; 2 fold, MEB55; 1.3 fold) 
of cyclin B1 protein levels (Figure 2F). Taken together, SL 
analogues regulate cyclin B1 in part by reduced mRNA 
synthesis and in part by enhanced protein degradation and 
employ alternative mechanisms to induce G2 arrest.
SL treatment induces a non-reversible decrease in 
cell viability 
Since SL prolonged the G2/M phase of the cell 
cycle and increased the accumulation of cells in the subG1 
fraction (Figure 2A and 2B), dual staining with Annexin 
V, and PI was employed. Annexin V is a marker of early 
Figure 3: Strigolactone analogues induce cell death via apoptosis. A, HCT116 cells were treated with the indicated concentrations 
of SLs for 24 hr. Cells were co-stained with annexin-V and PI and analyzed by flow cytometry. The distribution of HCT116 cells in early 
(Annexin-/PI+, gray bars) and late (Annexin+/PI+, black bars) apoptosis following SL treatment. B. Cell cycle distribution of DU145 cells 
treated with the indicated doses of MEB55 for 48 hr , washed with PBS and overlaid with fresh media without SL for additional 24 hrs and 
analyzed by flow cytometry. C-E. Assay of SL reversibility in cells. HCT116 (C), DU145 (D) and U2OS (E) cells were treated with the 
indicated SLs for the indicated times, the cells were washed with PBS and overlaid with fresh DMEM containing 10% FBS minus SLs. 
Changes in cell viability were assessed by an XTT assay and are shown as mean ±SD of triplicate wells and expressed as percent of control. 
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apoptosis, while PI only stains the chromatin of cells with 
compromised plasma membrane and therefore is a marker 
of late apoptosis. In HCT116 cells all five SL analogues 
increased the percentage of early (Annexin V+/PI-) and 
late (Annexin V+/PI+) apoptotic cells in a dose dependent 
manner (Figure 3A) and similar results were observed in 
two additional colon cancer cell lines, (SW480, HT29, 
Figure S2). 
Interestingly, we found that the inhibitory and 
apoptotic effects of SL analogues are non-reversible, as 
DU145 cells treated with MEB55 for 48 hrs were not able 
to recover and re-enter the cell cycle following removal 
of the analogue and replacement of the growth media 
with fresh growth media without MEB55 for additional 
24 hrs (24 hrs release). Cell cycle analysis showed that 
similar proportions of cells remained arrested at the G2/M 
checkpoint and there was no appreciable change in the 
subG1 fractions (Figure 3B). 
The rapid non-reversible effect of ST357, ST362 or 
MEB55 on cell viability of HCT116, DU145 and U2OS 
cells was determined following exposure of cells for 1, 4, 
8 or 24 hrs after which the different SLs were removed and 
media was replaced with fresh growth media for additional 
48 hrs release. While a short 1 hr exposure to any of the 
SL analogues produced only a modest non-reversible 
decrease in cell viability in the three cell lines (Figure 
3C-E), 4hrs exposure was sufficient to cause significant 
non-reversible reduction in cell viability as measured by 
XTT assays. U2OS cells exhibited the greatest sensitivity 
(Figure 3E) to SLs treatment, which correlates with the 
lower IC50 values in this cell line (Figure 1, Table 1). 
MEB55 was the most potent SL, and by 4 hrs treatments 
at the concentration of 10 ppm, only a small fraction of 
the cells remained viable (HCT116 18%; DU145 39% 
and U2OS 0% cells). As expected a further decrease in 
cell viability was observed when the three cell lines were 
exposed to SL for 8 hrs and 24 hrs.
Strigolactone analogues induce stress response 
signaling and inhibit survival signaling 
Members of the mitogen-activated protein kinases 
(MAPK) superfamily members play a pivotal role in 
cell survival and cell death. While ERK1/2 kinases are 
mostly involved in cell survival, the stress-related MAPK 
kinases, JNK1/2 and p38 elicit either pro- or anti apoptotic 
signals depending on signal intensity and tissue type [11]. 
Following treatment of DU145 cells with MEB55 for 1, 
4, 8 or 24 hrs, the expression and phosphorylation of the 
three main arms of the MAPK family (Erk1/2; JNK1/2 
and p38) were analyzed by immunoblotting (Figure 4A, 
Figure S4). p38 MAPK phosphorylation (pp38) was first 
evident at 4 hrs of SL treatment and remained elevated at 
24 hrs. Phosphorylation of HSP27, a downstream target 
of p38 [25], on Ser82 was increased in a similar time-
dependent manner as pp38 (Figure 4A). JNK1/2 displayed 
an acute and robust (15 fold increase) phosphorylation at 
4 hrs, which decreased by 50% at 8 hrs and returned to 
basal levels at 24 hrs. In contrast, pERK1/2 levels were 
reduced 4 fold after 1 hr of treatment and decreased further 
between 4 and 8 hrs. The levels of another survival factor, 
phosphorylated AKT/PKB, were decreased 6 fold at 8 
hrs and further decreased to undetectable levels at 24 hrs 
(Figure S4). While similar pattern of signaling activation 
was obtained in HCT116 cells (data not shown), in the 
non-immortalized ‘normal’ BJ fibroblast line (Figure 4B) 
that are resistant to synthetic SL analogue [3], pp38 levels 
remained largely unchanged and pERK1/2 levels were 
decreased only at 4 hrs. 
We next tested whether activation of p38 stress-
Figure 4: MEB55 modulates stress and survival 
signaling pathways. A. DU145 cells and B. BJ fibroblasts 
cells were treated with MEB55 (10 ppm) for the indicated times 
and resulting lysates were analyzed by immunoblot analysis 
with the indicated antibodies. C. DU145 and U2OS cells were 
pretreated for 1 hr with SB203580 at the indicated doses. After 
which time media was replaced with fresh media supplemented 
with SB203580 alone or in combination with MEB55 (DU145, 
10 ppm; U2OS, 5 ppm). Cells were incubated for a further of 6 hrs 
and HSP27 phosphorylation was analyzed by immunoblotting. 
D. Colony survival of DU145 cells as measured after pre-
treatment with 50 µM SB203580 for 2 hrs and then exposure 
to different concentrations of SL for additional 4 hrs. Cells were 
trypsinized, re-plated in triplicates and cultured for 14 days. 
SB203580 was replenished every other day. Colonies with >50 
cells were counted. Results represent mean of nine replicates 
±SD. **, P<0.01 as analyzed by linear regression and Student 
t-test.
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activated MAPK and/or JNK1/2 were required for SL 
induced growth inhibition and apoptotic induction. DU145 
and U2OS cells were pre-treated with pharmacological 
inhibitors of p38 (SB203580) and JNK1/2 (SP600125) 
prior to the addition of MEB55. While SB203580 was 
able to completely block pHSP27 phosphorylation (Figure 
4C), SP600125, only partially reduced the activation of 
JNK1/2 kinase (data not shown). Colony survival assays 
were performed in which U2OS cells were treated with 
50 µM SB203580 for 2 hrs prior to being treated with 
varying doses of MEB55 for additional 4 hrs and then re-
seeded in a limiting dilution to form colonies over 14 days. 
Treatment with SB203580 resulted in an incomplete but 
significant rescue of the SL inhibition of colony formation 
(Figure 4D), suggesting that both the p38/HSP27 axis and 
additional mechanisms are involved. 
Strigolactone induced stress response 
transcriptional program 
To assess the global transcriptomic effects of SL 
when growth inhibition and apoptosis of were initiated, 
U2OS cells were treated with 5 ppm of ST362 or MEB55 
for either 6 (Figure 5) or 24 hrs (Supplementary Table 2) 
to permit early and late gene expression changes to be 
distinguished. A marked stress response was observed 
after 6 hrs of SL exposure with elevated expression of 
heat shock proteins (HSPA6, HSPA7, HSP1A, HSP1B, 
HSPB8, HSPA1L, AHSA1) (Table 2, Figure 5) and 
stress-related transcription factors (ATF3, FOXO1 and 
DDIT3). Changes in apoptosis regulating genes were also 
identified, including DDIT3, BIRC3 and BAG3. BIRC3 
is an inhibitor of apoptosis and its expression was down 
regulated by both ST362 and MEB55. DDIT3 encodes 
Figure 5: Global changes in gene expression following treatment with ST362 or MEB55. A. U2OS cells were treated 
with vehicle or 5 ppm of ST362 or 5 ppm MEB55 for 6 hrs. Total RNA was extracted and analyzed by expression array. Results of two 
independent experiments are displayed as a Heatmap of genes differentially expressed in U2OS cells treated with MEB55 or with ST362 
for 6 hrs. Genes that were ±2 fold p≤0.05 upregulated are shown in red and down regulated transcripts are shown in green.  A representative 
list of individual genes at 6 hrs (±2 fold p≤0.05) is presented in Table 2 and at 24 hrs in Table S1. B-H qRT-PCR analysis of representative 
genes in A. I. A protein network of top upregulated genes in response to MEB55 and ST362 was constructed using the Ingenuity software. 
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Table 2: Classification of a representative list of SLs-responsive genes (6 hrs)  with at least 2 fold change. 
Function ACCESSION SYMBOL DEFINITION
Fold-
Change
ST362 
vs. control
p-value
Fold-
Change
MEB55 
vs. control
p-value
Stress
 Response NM_002155.3 HSPA6
Homo sapiens heat shock 70kDa protein 6 
(HSP70B') (HSPA6), mRNA.
79.8 2.55E-05 158.7 1.09E-05
NR_024151.1 HSPA7 Homo sapiens heat shock 70kDa protein 7 
(HSP70B) (HSPA7), non-coding RNA.
23.3 0.000290977 55.7 7.45E-05
NM_005346.3 HSPA1B Homo sapiens heat shock 70kDa protein 1B 
(HSPA1B), mRNA.
9.2 2.21E-06 12.4 1.05E-06
NM_005345.4 HSPA1A Homo sapiens heat shock 70kDa protein 1A (HSPA1A), mRNA. 7.3 6.92E-07 12.4 1.05E-06
NM_014365.2 HSPB8 Homo sapiens heat shock 22kDa protein 8 
(HSPB8), mRNA.
2.7 1.43E-05 3.6 3.18E-06
NM_005527.3 HSPA1L Homo sapiens heat shock 70kDa protein 1-like (HSPA1L), mRNA. 2.7 0.00238603 3.9 0.00044493
NM_012111.1 AHSA1 Homo sapiens AHA1, activator of heat shock 90kDa protein ATPase homolog 1 (yeast 2.1 0.0136702 2.6 0.0044504
Growth 
Factors NM_002632.4 PGF
Homo sapiens placental growth factor (PGF), 
mRNA. 6.2 0.0001284 7.0 8.86E-05
Cytokines/
Signaling NM_004864.1 GDF15
Homo sapiens growth differentiation factor 15 
(GDF15), mRNA.
7.6 3.16E-05 19.0 3.66E-06
NM_001001437.3 CCL3L3 Homo sapiens chemokine (C-C motif) ligand 
3-like 3 (CCL3L3), mRNA.
3.7 0.0371505
NM_001024847.1 TGFBR2 Homo sapiens transforming growth factor, beta 
receptor II (70/80kDa) (TGFBR2), t
-2.0 0.0158406 -2.3 0.00859784
Apoptosis NM_004083.4 DDIT3 Homo sapiens DNA-damage-inducible transcript 3 (DDIT3), mRNA. 6.2 0.000961245 14.1 0.000126234
NM_004281.3 BAG3 Homo sapiens BCL2-associated athanogene 3 
(BAG3), mRNA.
4.6 3.87E-05 7.7 7.20E-06
NM_001165.3 BIRC3 Homo sapiens baculoviral IAP repeat-containing 
3 (BIRC3), transcript variant 1,
-2.4 0.00864687 -3.2 0.002218
Cellular 
adhesion NM_181702.1 GEM
Homo sapiens GTP binding protein 
overexpressed in skeletal muscle (GEM), 
transcript.
2.4 0.00147308 4.9 1.53E-05
NM_012129.2 CLDN12 Homo sapiens claudin 12 (CLDN12), mRNA. 2.3 0.00116056 2.5 0.000758471
Cell Cycle 
Regulation
NM_004354.1
NM_031966.2
CCNG2
CCNB1
Homo sapiens cyclin G2 (CCNG2), mRNA.
Homo sapiens cyclin B1 (CCNB1), mRNA
3.6
-2.1
1.59E-05
0.00562257 3.1 3.16E-05
Metabolism NM_001013251.1 SLC3A2 Homo sapiens solute carrier family 3 (activators of dibasic and neutral amino ac 3.6 0.00297397 3.4 0.00378565
NM_020428.2 SLC44A2 Homo sapiens solute carrier family 44, member 
2 (SLC44A2), mRNA.
2.5 0.00318131 2.1 0.00883196
NM_001860.2 SLC31A2 Homo sapiens solute carrier family 31 (copper 
transporters), member 2 (SLC31A2),
2.3 8.51E-05
NM_014331.3 SLC7A11 Homo sapiens solute carrier family 7, (cationic amino acid transporter, y+ syste 2.2 0.0388166 2.1 0.0461742
NM_000927.3 ABCB1 Homo sapiens ATP-binding cassette, sub-family 
B (MDR/TAP), member 1 (ABCB1), mRN
3.6 0.000245971 8.1 1.49E-05
NM_000963.1 PTGS2 Homo sapiens prostaglandin-endoperoxide 
synthase 2 (prostaglandin G/H synthase a
3.4 0.0294943 6.9 0.00419823
NM_014330.2 PPP1R15A Homo sapiens protein phosphatase 1, regulatory (inhibitor) subunit 15A (PPP1R15A 2.7 0.000380118 3.7 7.56E-05
NM_000782.3 CYP24A1 Homo sapiens cytochrome P450, family 24, 
subfamily A, polypeptide 1 (CYP24A1), n
-2.6 0.000579055 -3.6 0.000113939
NM_000692.3 ALDH1B1 Homo sapiens aldehyde dehydrogenase 1 family, 
member B1 (ALDH1B1), nuclear gene
-2.1 0.00210428 -3.1 0.00430455
Transcription NM_001040619.1 ATF3 Homo sapiens activating transcription factor 3 (ATF3), transcript variant 4, mRN 2.2 0.0184042 4.0 0.00147967
NM_005938.2 FOXO4 Homo sapiens forkhead box O4 (FOXO4), mRNA. 2.5 0.000437924 2.2 0.000948698
NM_004472.2 FOXD1 Homo sapiens forkhead box D1 (FOXD1), mRNA. -2.4 0.0361717 -2.7 0.0212245
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a member of the CCAAT/enhancer-binding protein (C/
EBP) family of transcription factors that is induced by 
stress including DNA damage. Moreover, DDIT3 over-
expression can induce cell cycle arrest [32, 33] and indeed 
both MEB55 and ST362 treatment was associated with 
changes in cell cycle-related gene expression. MEB55 
treatment was associated with increased expression 
of p21cip (CDKN1A), Cyclin F (CCNF), Cyclin A2 
(CCNA2) and decreased expression of CDK6. Consistent 
with our earlier data, ST362 induced a modest down-
regulation of Cyclin B1 (CCNB1) expression. Both 
MEB55 and ST362 induced Cyclin G2 (CCNG2), an 
unconventional cyclin homolog, which is linked to 
growth inhibition and whose expression is induced by 
DNA damaging chemotherapeutics [34]. SL exposure also 
induced changes in the expression of genes involved in 
metabolic functions in tumor and stem cells (ALDH1B1, 
ABCB1, SLC3A2, SLC44A2, SLC31A2, SLC7A11, 
CYP24A1, PTGS2/COX2, PPRC1), cytokines (CCL3L3, 
GDF15) and growth and differentiation factors (PGF, 
TGFBR11 and FOXD1).
At 24 hrs Supplementary Table 1, SL treatment was 
associated with down regulation of cell cycle regulators, 
including cyclins (CCNB2, CCNA2, CCNF) and cyclin 
regulatory proteins (CCNBP1 (cyclin B binding protein), 
CDKN3 (CDK inhibitor 3, a dual specificity phosphatase 
Figure 6: Enhanced sensitivity of primary prostate cancer cells to MEB55 and ST362. Normal prostate and prostate tumor 
CRCs were treated for 48 hrs with (A) MEB55 or (B) ST362. Cell viability was measured using the XTT cell viability assay. The IC50 of 
MEB55 is 1.8 ppm in tumor cells (95% confidence interval [CI], 0.294- to 0.427) and >20 ppm in normal cells (95% CI, 0.82 to 1.69), 
with statistical selectivity for tumor versus normal cells (P<0.0001)***. The IC50 for ST362 is 2.3 ppm in tumor CRCs (95% CI, 0.33-0.85) 
versus >20 ppm in normal CRCs (95% CI, 0.90 -1.1) with selectivity for tumor versus normal p<0.0001***. C. Cell cycle analysis of 
conditionally-reprogrammed normal and tumor prostate cells treated with IC50 concentrations of MEB55 or ST362 for 48 hrs. Cell Cycle 
analysis was performed by flow cytometry. D. Prostate tumor CRCs were treated with vehicle or the indicated concentrations of MEB55 and 
were analyzed for changes in expression of cyclin B, total and phosphorylated p38 MAPK and PARP1 cleavage by immunoblot analysis. 
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and an inhibitor of CDK2 activity), CDCA3, CDC20, 
CDC25C, CDCA2), the transcription factor E2F as well 
as mitotic genes involved in cytokinesis (KIF23, KIF4A, 
KIF11, KIFC1, KIF2C, KIF20A, IF15). The 24 hrs SL 
treatment resulted in up-regulation of genes involved in 
RNA processing and translation (RN7SK, SNORD3A, 
SNORD3C, SNORD3D) and altered expression of 
metabolic genes (DHRS2, SLC7A11, DUSP5, SCG5, 
ABCA13), growth factors (TGFB1, CTGF) and altered 
expression of genes involved in cellular adhesion 
(LAMA1, AMPH, ITGA2, SPP1/OPN1, ESM1, CYR61). 
ESM1 expression was the second (21.2-fold) and 
third (6.9-fold) most up-regulated gene in MEB55 and 
ST362 treated groups respectively. ESM1 is a secretory 
proteoglycan, whose expression is up-regulated by 
inflammatory cytokines. Altered expression of ESM1 has 
also been shown to induce cell cycle arrest [35] (Table 
S1). To validate the gene expression array data, qRT-PCR 
was carried out on 7 genes of which some were the most 
altered genes. HSPA6, HSPA1B, Cyp24A, ALDH1, ATF3, 
FOXD1 and FOXO4 exhibited similar expression pattern 
changes when analyzed by qRT-PCR as that observed by 
array analysis (Figure 5B-H). 
Next we used the IPA database (Ingenuity® 
Systems, www.ingenuity.com) to identify networks and 
pathways of genes induced following 6 hrs exposure to 
SL analogues. The top up regulated genes confirmed a 
general up-regulation of stress and apoptotic responses 
that interestingly converge into the p38 pathway (Figure 
5I).
Strigolactone therapeutic potential 
To further explore the possible therapeutic potential 
of the SLs analogous, we utilized the novel model system 
of conditionally reprogramed cells (CRCs) [36], co-
developed by us to permit the continuous culture of a wide 
spectrum of normal and malignant epithelium [28]. Both 
primary normal and tumor cells were obtained from the 
same patient and can be propagated indefinitely in vitro in 
the presence of irradiated murine 3T3 J2 fibroblast feeder 
cells, and Rho kinase inhibitor, Y-27632, as previously 
described [28, 29, 37]. Matched normal and tumor 
prostate cells were treated with different concentrations 
of SL analogues MEB55, ST362, ST357 and EG9 and the 
viability of cells was measured by XTT assays (Figure 
6A, 6B and S5). All SLs reduced the viability of prostate 
tumor CRCs with MEB55 and ST362 being most potent 
and effective. The IC50 of MEB55 in the prostate tumor 
CRCs is 1.8 ppm 95% confidence interval [CI95%] 0.294-
0.427 while the IC50 of MEB55 in normal prostate CRCs 
is extrapolated to be > 20 ppm and selectivity for tumor 
versus normal cells is highly significant at (p<0.001). 
Similarly, the IC50 of ST362 in tumor cells is 2.3 ppm 
[CI95%] 0.593 to 0.702 p< 0.001. The IC50 of ST357 in 
tumor cells is 5.649 ppm [CI95%] 0.647-0.826 p<0.001. 
None of the analogues caused more than 50% growth 
inhibition of normal prostate cells at the concentrations 
used. 
Cell cycle analysis of primary normal and tumor 
prostate cells treated with vehicle, or with the identified 
IC50 concentration of MEB55 and ST362 indicated a 
significant increase in the subG1 fraction of tumor cells 
in response to MEB55 or ST362 (from 6% in control to 
40% or 37% respectively, p<0.007), with only a slight 
increase in subG1 that was noted in normal cells (P =0.4) 
(Figure 6C). To identify the molecular changes associated 
with the cellular response of normal and tumor CRC cells 
to SLs, cells were treated with the IC50 concentrations of 
MEB55 followed by immunoblotting for cyclin B, pp38 
as described above. Despite the lack of measureable G2/M 
cell cycle arrest, MEB55 caused a dramatic reduction in 
cyclin B expression in tumor CRC cells and a pronounced 
stress response was elicited by the three different SLs 
as determined by induction of pp38 (Figure 6D). In 
addition, the assay for PARP1 cleavage confirmed the 
robust apoptotic response observed in the tumor derived 
CRCs versus the patient-matched normal CRCs from 
the same patient (Figure 6D). Taken together, these data 
indicate that SL analogues can induce significant and non-
reversible apoptotic response in both transformed cancer 
cell lines and in patient-derived tumor cells, while sparing 
normal cells and therefore may be useful therapeutic 
reagents.  
DISCUSSION
The present study sought to investigate the anti-
tumorigenic effects of synthetic analogues of the 
strigolactone hormone towards human cancer cells. The 
array of cell lines used was chosen based on their diverse 
origin and oncogene expression status. We show that SL 
analogues inhibit the growth of different cancer cell lines 
including prostate, colon, lung and osteosarcomas. SLs 
also induced cellular stress response leading to cell cycle 
arrest and apoptosis in all tumor cells tested but not in 
normal fibroblasts. While the mechanisms of SLs growth 
inhibition only begin to unfold, our results indicate that 
SLs induce G2 cell cycle arrest in all cells regardless of 
their underlying genetic alterations, e.g. p53, k-ras or 
nuclear receptor status. We further show that SLs are 
effective in targeting human primary prostate cancer cells 
while being significantly less toxic to normal prostate 
cells of the same patient, suggesting that SLs might be 
treatment option in advanced prostate cancer. 
SL-induced cell cycle arrest is likely mediated by 
down regulation of Cdc25C (Figure 2 and TableS1) and 
cyclin B1 mRNA and protein levels (Figure 2, Table 2 and 
Table S1). We found that down-regulation of cyclin B was 
partially rescued by proteasomal inhibition, suggesting 
that SLs regulate the expression of cyclin B at least in 
part by protein degradation via the ubiquitin-proteasome 
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pathway. Interestingly, in Arabidopsis as well as in other 
plants, SLs inhibit root formation by down regulating 
cyclin B expression via the ubiquitin–proteasome pathway 
[38], suggesting the mechanisms of cyclin B regulation by 
SL are conserved between plants and mammals. 
MEB55 and ST362 are the most potent SLs and 
induce apoptosis in all tested cancer cell lines. Significant 
loss of cell viability was initiated between 1 to 4 hrs of SLs 
exposure (depending on the cell line and analogue) and 
was non-reversible even after removal of the SLs. Notably, 
SLs induced apoptosis even at lower concentrations in 
the primary prostate tumor cells, which was confirmed 
by PARP1 cleavage. SLs had only minimal effect on the 
patient-matched primary normal prostate cells. We found 
that SLs induce the expression of several pro-apoptotic 
genes and inhibit the expression of several survival factors 
including the stemness marker, ALDH1, which is critical 
for viability and self-renewal of stem cells. These data 
support our previous finding that SLs inhibit self-renewal 
and are highly potent towards stem-like enriched cells 
[3]. We also noted the transient inhibition of ERK1/2 and 
a more durable inhibition of AKT in response to SLs. 
Inhibition of the PI3-K/AKT pathway has been shown to 
play an important role in the cytotoxic effects of another 
plant hormone, Methyl Jasmonate [39].
The activation of stress signaling is likely to be an 
important contributing factor to SLs’ induced cell cycle 
arrest and apoptosis. Array analysis revealed induction 
of multiple heat shock proteins and cytokines by 6 hrs 
following SLs exposure, which was validated by  qRT-
PCR. HSP6A and HSP7A, the highest inducible genes 
(20-158 fold induction), are members of HSP70 family 
that act to stabilize proteins against aggregation and 
misfolding. While many tumors express high levels of 
some HSP70 members, under extreme stress conditions 
and DNA damage, the induction of HSP expression, 
especially HSP6A contributes to cell cycle arrest and 
apoptosis [40]. Interestingly, a protein network constructed 
from the top up-regulated genes in response to SLs 
clearly indicate the activation of stress related network 
with p38 as the main focal point, further supporting our 
biochemical observations. In addition, the expression of 
stress-induced transcription factor, FOXO4, which is often 
phosphorylated and activated by JNK [41] is up regulated 
in response to SLs. Furthermore, we show that p38 MAPK 
and JNK1/2 were activated as early as 4 hrs following 
SL exposure. The functions of JNK and p38 MAPK in 
cancer cells are complex; P38 MAPK and JNK1/2 play 
a crucial role in cellular stress responses, signaling for 
cell cycle arrest [42] and apoptosis [17, 43], yet, in some 
cases p38 MAPK and JNK enzymes are associated with 
cell survival, aggressive cancer phenotypes including 
invasiveness. Interestingly, pharmacological inhibition of 
p38 MAPK only partially alleviated the inhibitory effects 
of SLs treatment, while pharmacological inhibition of 
JNK1/2 together with SLs was toxic. Taken together, these 
data indicate that additional pathways may be involved in 
mediating SLs growth inhibitory effects, and the precise 
mechanisms remain to be determined. 
The innovative technology of conditionally 
reprogramed cells (CRCs) is an attractive system for 
drug discovery in the era of “targeted therapy” and 
“personalized medicine”. 
This system of long term cultures of matched normal 
and cancer cells that originated from biopsies of the same 
patient was recently described [28, 29, 37] and enables 
evaluation of the therapeutic index of new compounds 
including toxicity and efficacy for individual patients. 
Here we used matched cultures of normal and 
tumor prostate cells obtained from a patient diagnosed 
with gleasons grade 7 prostate cancer. We show enhanced 
sensitivity of tumor cells to the two most potent SLs: 
MEB55 and ST362 over normal cells, supporting the 
selectivity of these SLs seen in cancer cell lines. Taken 
together, our data suggest that SLs may be promising 
candidates as broad-spectrum anti-cancer agents eliciting 
cell cycle arrest and apoptosis via modulation of stress 
signaling and abrogation of cell survival pathways. Further 
studies are warranted to determine whether the current 
findings can be applicable to other cases of advanced 
prostate cancer. 
METHODS
Cell culture
Cells were grown at 37 °C in a humidified 5% 
CO2-95% air atmosphere. All tissue culture media and 
serum were purchased from Gibco (Invitrogen), unless 
otherwise indicated. LNCaP, DU145, PC3, A549 were 
maintained in RPMI supplemented with 10% FCS and 
HCT116, SW480, HT-29, U2OS (ATCC, Manassas) 
were maintained in DMEM supplemented with 10% FCS 
(Atlanta Biologicals). 
Conditionally reprogramed cells
Human radical prostatectomy samples were 
collected under the auspices and approval of the 
Massachusetts General Hospital Institutional Review 
Boards. Following detailed pathological analyses that 
documented that the tissue sections collected were nearly 
exclusively comprised of either tumor or normal cells, the 
specimens were processed and established using the CRC 
method as previously described [28, 29, 37]. The CRC 
cultures were maintained as described on irradiated 3T3 
J2 murine fibroblasts in DMEM/F12-medium (Invitrogen) 
containing 10 mM Y-27632 (Enzo Life Sciences) and were 
passaged every 3–4 days due to rapid proliferation induced 
by the ROCK inhibitor. After removal of the feeder cells, 
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confluent human prostate cells (HPCs) were detached 
by trypsin treatment and passaged 1:10 (4.2 × 105 HPCs 
per 75-cm2 tissue culture flask) for 3 days or 1:20 (2.1 
× 105 HPCs per 75-cm2 flask) for 4 days onto freshly 
irradiated feeders.
Strigolactone treatments and Reagents
Hormones were solubilized in Acetone (Sigma) at 
stock concentrations of 5000.0 ppm. Cells were treated at 
the indicated doses by diluting the hormone to the required 
highest concentration in the appropriate culture medium. 
Serial dilutions were performed for subsequent lower 
concentrations and final vehicle concentrations equalized. 
N-Acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN) was 
purchased from Sigma. SB203580 and SP600125 were 
purchased from Cell Signaling Technology (Danvers, 
MA). All inhibitors were solubilized in DMSO according 
to the manufacturer’s instructions.
XTT Viability Assay 
Cells were seeded into a 96 well plates at 1500 
cells per well in triplicates in normal growing media. 
The following day media was replaced with phenol-free 
DMEM supplemented with 10% charcoal stripped serum 
and the indicated final concentrations of Strigolactone 
analogue or vehicle (acetone) alone. Cells were incubated 
for 3 days, at which time XTT (2, 3,-bis(2-methoxy-4-
nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-
tetrazolium inner salt) reduction was used to quantify 
viability according to manufacturer’s instruction 
(ATCC). Cells were incubated with XTT reagent for 
2-3 hrs at 37 °C in a humidified 5% CO2-95% air 
atmosphere. Absorbance was recorded by a photometer 
SPEKTRAFluor Plus, Tecan (Salzburg, Austria) at 450 nm 
with 750 nm of reference wavelength. Cell survival was 
estimated from the equation: % cell survival = 100 × (At-
Ac), where At and Ac are the absorbencies (450nm) of the 
XTT colorimetric reaction (ATCC) in treated and control 
cultures respectively minus non-specific absorption 
measured at 750nm. Absorbance of medium alone was 
also deducted from specific readings.
Cell Cycle Analysis and phosphoHistone-H3 
staining
Cells were seeded at densities of 2 × 105 cells 
(SW480, HT-29) or 5 x 105 cells (HCT116) per well in 
10% DMEM in 6-well plate culture dishes. The following 
day, the media was replaced with phenol-free DMEM 
supplemented with 10% charcoal-stripped FBS with the 
indicated concentrations of SL or vehicle alone (acetone). 
After 48 hrs, cells were washed twice with 1 x PBS (pH 
7.4), centrifuged at 360g for 10 min at 4oC, and fixed 
in chilled ethanol (70%; v/v in PBS) with gentle vortex 
mixing. To determine their DNA contents, the cells were 
stained with 40 µg/ml propidium iodide (PI) and analyzed 
using a FACSCalibur flow cytometer and CellQuest 
analysis software (Becton Dickinson, San Jose, CA). 
Where phosphoHistone-H3 staining was carried out, cells 
were incubated with polyclonal antibody against phospho-
Histone H3 and then with secondary Goat anti-rabbit IgG- 
conjugated to FITC prior to PI staining.
Annexin V staining
Cells were cultured for 48 hrs under the same 
conditions as those used for the DNA content/cell cycle 
analysis. All the cells were collected and resuspended in 
100 µL 1 X Annexin V Binding Buffer (BD Biosciences, 
San Jose, CA, USA). 2 µL FITC-Annexin V (BD 
Biosciences) was added and incubated for 10 mins in 
the dark (room temperature).  Cells were then stained 
with PI (Sigma, Saint Louis, Missouri, USA) to a final 
concentration of 40 µg/mL and the cells were incubated 
at room temperature for 15 min in the dark. Then, 400 
µL of Annexin V binding buffer were added and flow 
cytometry was performed using a BD FACSCalibur flow 
cytometer. Cells were considered to be apoptotic if they 
were Annexin V+/PI- (early apoptotic) and Annexin V+/
PI+ (late apoptotic). Each analysis was performed using at 
least 20,000 events. 
Immunoblotting analysis
 Whole cell lysates were prepared using a lysis 
buffer containing: 50 mM Tris-HCl (pH 7.5), 0.5% 
NP-40, 0.1% SDS, 0.25% sodium deoxycholate, 125 
mM NaCl, 1 mM EDTA, 50 mM NaF, 1 mM sodium 
orthovanadate, 2.5 mM sodium pyrophosphate, 1 mM 
sodium β-glycerophosphate, 1 mM PMSF, and a protease 
inhibitor cocktail (Roche Molecular Biochemicals) and 
cleared by centrifugation. Protein concentration was 
determined using the BCA Protein Assay (Pierce), and 
20–50 µg of lysate were separated in a 4–12% SDS-PAGE 
gel. After transfer, membranes were blocked for 30 min 
at room temperature in 5% BSA (Sigma) in Tris-buffered 
saline containing 0.1% Tween-20. Primary antibody 
was incubated for either 1.5 hrs at room temperature or 
overnight at 4°C. Secondary antibody was incubated for 
30 min at room temperature, and proteins were visualized 
with West Pico Stable (ThermoScientific). All antibodies 
were used at 1:1000 dilution unless otherwise stated. 
pT308AKT, AKT, pT180/Y182 P38 MAPK, P38 MAPK, 
pERK1/2, ERK1. pS82HSP27, pT183/Y185 JNK1/2, 
JNK1, pT14 Cdk1, Cdk1 , α-tubulin (1:20,000, Sigma-
Aldrich), Cyclin B1 (Santa Cruz Biotechnologies) and 
horseradish peroxidase-conjugated anti-rabbit IgG and 
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anti-mouse IgG (1:5,000, Jackson Immunoresearch). 
Densitometric quantifications of the immunoblots were 
carried out using ImageJ software (NIMH).
Colony Survival Assay
U2OS cells were either pre-treated with 50 µM 
SB203580 for 2 hrs or treated with different doses of 
MEB55 for 6 hrs. Cells were then trypsinized and re-
seeded in triplicates in limited dilutions of 2x103 cells/
well in 6 well plates. Cells were allowed to form colonies 
for 14 days during which SB203580 was replenished 
every other day. Cells were fixed and stained with crystal 
violet and 70% EtOH. Colonies of 50 cells or more were 
counted. 
Statistical Analysis
Results are presented as mean ± SD of replicate 
analyses and are either representative of, or inclusive 
of at least two independent experiments. Statistical 
comparisons between two experimental groups were 
performed using student’s t-test (2-tailed, paired) whilst 
multiple group comparisons were performed using 
analysis of variance (ANOVA). Data regarded as being 
significant when P < 0.05 (*). Higher power is significance 
(p<0.01**, p<0.001***) are also employed and indicated 
in each figure legend. IC50 doses for SLs were calculated 
by interpolation of the sigmoidal dose response curves 
(Graphpad Prism 6.0 software).
Gene expression analysis 
Total RNA was prepared from cells treated with 
either ST362 or MEB55 (5ppm) for either 6 hrs or 24 hrs 
using Trizol (Invitrogen, Carlsbad, CA, USA) according 
to the manufacturer’s protocol. RNA purity was assessed 
by an A260/A280 ratio of ≥1.9, and by the integrity of 18S 
and 28S rRNA using an Agilent microfluidic chip. Array 
analysis was carried out on cDNA prepared from equal 
amounts of RNA (5 μg) prepared from duplicate sample 
sets. Labeled cRNA was denatured and fragmented at 94°C 
for 35 min and then hybridized overnight to an Illumina 
human GeneChip representing approximately 14,000 
annotated human genes. Expression microarray image was 
initially processed by Illuminia® GenomeStudio®, which 
outputs the pre-processed data. The pre-processed sample 
intensities then were imported into Partek® Genomics 
SuiteTM for the differential analysis test. Two-way ANOVA 
model was utilized, and the two factors are Time (6-hrs, 
24-hrs) and Drug Treatment (MEB55, ST362). Four 
contrasts of the “Drug Treatment – Time” interaction 
was tested, they are “MEB55-6hour vs. Control-6hour”, 
“MEB55-24 hrs vs. Control-24 hrs”, “ST362-6hour vs. 
Control-6hour”, “ST362-24hour vs. Control-24hour’. The 
combination of the raw p-value < 0.05 and absolute Fold 
change > 2 was set as the cutoff to select the significantly 
expressed genes in each of above contrasts. The Benjamini 
Hochberg multiple testing correction was utilized to 
calculate the False Discovery Rate (FDR) as a reference. 
Gene lists were refined by eliminating genes with signal 
intensities <100 (log2=6.64) in both comparison groups.
Quantitative Real-Time Polymerase Chain 
Reaction (qRT-PCR)
Total RNA was extracted using Trizol (Invitrogen, 
Carlsbad, CA, USA) using the manufacturer’s protocol. 
1μg RNA was reverse-transcribed in a total volume of 20 
μl using the High Capacity cDNA kit (Invitrogen). Primers 
were designed using PrimerQuest software (Integrated 
DNA Technologies). PCR was performed in triplicate 
using an ABI-Prism 7900 instrument (Invitrogen, Foster 
City, CA) and SYBR Green (Invitrogen, Foster City, CA) 
according to the manufacturer’s protocol. The expression 
of each target gene was normalized to the expression of 
GAPDH mRNA and is presented as the ratio of the target 
gene to GAPDH RNA, expressed as 2-ΔCt, where Ct is 
the threshold cycle and ΔCt = Ct Target - Ct GAPDH. 
Experiments were repeated three times.
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